Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate ...

As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...

Summit Therapeutics (NASDAQ:SMMT) has entered a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (NYSE:PFE) antibody drug conjugates across multiple ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly diagnosed cancer and the second leading cause of cancer-related death for U.S. men. This ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Summit Therapeutics, Inc. shares rebounded in after-hours trading on Monday after a 14% selloff during regular hours, with ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...